gestational diabetes
Jump to navigation
Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]
Etiology
- no strong evidence supports a causal effect of vitamin D status on gestational hypertension or pre-eclampsia[22]
- antidepressant use during pregnancy
- RR= 1.2; SNRI RR=1.3; tricyclic antidepressants RR=1.5; venlafaxine RR=1.3; amitriptyline RR=1.5 [25]
Epidemiology
- 2-4% of pregnancies with prevalence increasing[7]
- 7% of pregnancies[1]
- higher incidence in Native Americans, blacks & hispanics
Pathology
- insulin-resistance
- normally develops in 3rd trimester
- inadequately compensatated by islet cell hyperfunction
Clinical manifestations
- develops around 7th month of pregnancy
Laboratory
Step 1 glucose tolerance test*
- 50 grams of oral glucose
- 1 hour serum glucose > 140 mg/dL, proceed to step 2
Step 2 glucose tolerance test
- 100 grams of glucose load
- fasting serum glucose > 95 mg/dL
- 1 hour serum glucose > 180 mg/dL
- 2 hour serum glucose > 155 mg/dL
- 3 hour serum glucose > 140 mg/dL
- positive test is 2 or more criteria met
* All pregnant women should be screened after 24 weeks[12]
Complications
- maternal risks
- 50% will develop type-2 diabetes within 5-10 years[1]
- fetal risks (treatment reduces serious risk[4])
- intrauterine death
- acute respiratory distress syndrome
- hypoglycemia*
- hypocalcemia
- polycythemia*
- hyperviscosity
- hyperbilirubinemia (develops after birth)
- cardiomyopathy
- macrosomia (most common)
- shoulder dystocia
- bone fracture
- nerve palsy
- treatment reduces preeclampsia, shoulder dystocia, & macrosomia[10]
- increased risk of autism in offspring (RR=1.42)[16]
- progression to type 2 diabetes
- breast feeding may lower risk[18]
- gestational diabetes increases maternal risk of cardiovascular disease
- healthy lifestyle habits in midlife may mitigate this risk[20]
- increased risk of early-onset cardiovascular disease in offspring (RR=1.2)[26]
* risk at birth[27]
Management
- goals:
- fasting blood glucose < 90 mg/dL
- 1 hour post-prandial glucose < 120 mg/dL[1]
- successfully treated with diet in most patients
- avoid ketosis associated with carbohydrate deprivation
- Mediterranean diet may lower risk for gestational diabetes[24]
- insulin is probably safest choice if diet ineffective
- oral hypoglycemics may see more use[8]
- metformin is probably safe[5]
- glyburide
- should not be used in pregnant women[14][15]
- somewhat more effective than metformin in controlling hyperglycemia in mom[8][14]
- may be an acceptable agent for women unable to tolerate insulin[2]
- excess risk for adverse neonatal outcomes with glyburide[23]
- associated with higher rates of macrosomia & neonatal hypoglycemia than insulin or metformin[14]
- increased risk for neonatal ICU admission (10.2 vs 7.2%), respiratory distress (2.9 vs 1.7%), hypoglycemia (1.9% vs 1.3%), birth injury (2.2 vs 1.6%), & macrosomia (4.7 vs 3.2%) relative to treatment with insulin[15]
- composite outcome of macrosomia, neonatal hypoglycemia, & hyperbilirubinemia 27.6% with glyburide vs 23.4% with insulin[21]
- GLP-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, or flozins not associated with increased risk of birth defects[29]
- hypoglycemia is common, but NOT clearly associated with risk to fetus
- screening:
- eye examination once per trimester[1]
- prevention:
- healthy lifestyle factors (regular exercise, normal weight, healthy diet, no smoking) may reduce risk by at least 40%[13]
- in obese women, myo-inositol 4 grams daily may reduce risk of gestational diabetes[17]
- followup
- screening for diabetes at 6-12 weeks postpartum & every 3 years thereafter[1]; annual screening[1]
More general terms
Additional terms
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Medical Knowledge Self Assessment Program (MKSAP) 11, 15, 16, 17, 19. American College of Physicians, Philadelphia 1998, 2009, 2012, 2015, 2022
Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022 - ↑ 2.0 2.1 Prescriber's Letter 7(12):71 2000 Journal Watch 20(24):192, 2000 Langer et al, N Engl J Med 343:1134, 2000
- ↑ Journal Watch 23(5):42, 2003 US Preventive Services Task Force, Obstet Gynecol 101:380,2003 http://www.ahrq.gov/clinic/3rduspstf/gdm/
- ↑ 4.0 4.1 Journal Watch 25(16):131, 2005 Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005 Jun 16;352(24):2477-86. Epub 2005 Jun 12. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15951574
Greene MF, Solomon CG. Gestational diabetes mellitus -- time to treat. N Engl J Med. 2005 Jun 16;352(24):2544-6. Epub 2005 Jun 12. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15951575 - ↑ 5.0 5.1 Prescriber's Letter 15(7): 2008 Pregnancy and Diabetes: Updated Information about Metformin Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=240704&pb=PRL (subscription needed) http://www.prescribersletter.com
Hollander MH, Paarlberg KM, Huisjes AJ. Gestational diabetes: a review of the current literature and guidelines. Obstet Gynecol Survey 2007;62:125-36 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17229329 - ↑ Norris SL, Kansagara D, Bougatsos C, Fu R; U.S. Preventive Services Task Force. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2008 Jun 3;148(11):855-68. Review. Summary for patients in: Ann Intern Med. 2008 Jun 3;148(11):I30. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18519931
U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008 Jun 3;148(11):846-54. Erratum in: Ann Intern Med. 2008 Jul 15;149(2):147. Summary for patients in: Ann Intern Med. 2008 Jun 3;148(11):I30. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18519930 (corresponding NGC guideline updated March 2014) - ↑ 7.0 7.1 Getahun D, Nath C, Ananth CV, Chavez MR, Smulian JC. Gestational diabetes in the United States: temporal trends 1989 through 2004. Am J Obstet Gynecol. 2008 May;198(5):525.e1-5. Epub 2008 Feb 15. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18279822
- ↑ 8.0 8.1 8.2 Prescriber's Letter 17(3): 2010 Oral Agents for Gestational Diabetes Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260303&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Landon MB, Gabbe SG. Gestational diabetes mellitus. Obstet Gynecol. 2011 Dec;118(6):1379-93. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22105269
- ↑ 10.0 10.1 U.S. Preventive Services Task Force (USPSTF) Screening for Gestational Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. DRAFT. Summary of Recommendation and Evidence http://www.uspreventiveservicestaskforce.org/draftrec2.htm
Hartling L et al Benefits and Harms of Treating Gestational Diabetes Mellitus: A Systematic Review and Meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Annals of Internal Medicine. May 28, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23712381 <Internet> http://annals.org/article.aspx?articleid=1691700 (corresponding NGC guideline withdrawn Jan 2014) - ↑ Donovan L et al Screening Tests for Gestational Diabetes: A Systematic Review for the U.S. Preventive Services Task Force Annals of Internal Medicine. May 28, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23712349 <Internet> http://annals.org/article.aspx?articleid=1691699
- ↑ 12.0 12.1 12.2 Moyer VA et al Screening for Gestational Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. Published online 14 January 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24424662 <Internet> http://annals.org/article.aspx?articleid=1813285
- ↑ 13.0 13.1 Zhang C et al Adherence to healthy lifestyle and risk of gestational diabetes mellitus: prospective cohort study. BMJ 2014;349:g5450 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25269649 <Internet> http://www.bmj.com/content/349/bmj.g5450
Meltzer SJ Unhealthy lifestyles and gestational diabetes. BMJ 2014;349:g5549 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25270049 <Internet> http://www.bmj.com/content/349/bmj.g5549 - ↑ 14.0 14.1 14.2 14.3 14.4 Balsells M et al Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015;350:h102 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25609400 <Internet> http://www.bmj.com/content/350/bmj.h102
Sacks DA Which oral hypoglycaemic for gestational diabetes? BMJ 2015;350:h177 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25608802 <Internet> http://www.bmj.com/content/350/bmj.h177 - ↑ 15.0 15.1 15.2 Camelo Castillo W et al Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes. JAMA Pediatr. Published online March 30, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25822253 <Internet> http://archpedi.jamanetwork.com/article.aspx?articleid=2211139
Holt RIG Glyburide for Gestational DiabetesTime for a Pause for Thought. JAMA Pediatr. Published online March 30, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25821923 <Internet> http://archpedi.jamanetwork.com/article.aspx?articleid=2211136 - ↑ 16.0 16.1 Xiang AH, Wang X, Martinez MP et al Association of Maternal Diabetes With Autism in Offspring. JAMA. 2015;313(14):1425-1434 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25871668 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=2247143
- ↑ 17.0 17.1 D'Anna R et al. Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women: A randomized controlled trial. Obstet Gynecol 2015 Aug; 126:310 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26241420 <Internet> http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2015&issue=08000&article=00014&type=abstract
- ↑ 18.0 18.1 Gunderson EP et al Lactation and Progression to Type 2 Diabetes Mellitus After Gestational Diabetes Mellitus: A Prospective Cohort. Ann Intern Med. Published online 24 November 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26595611 <Internet> http://annals.org/article.aspx?articleid=2471594
- ↑ Committee on Practice Bulletins--Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. Obstet Gynecol. 2013 Aug;122(2 Pt 1):406-16 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23969827
- ↑ 20.0 20.1 Tobias DK, Stuart JJ, Li S et al. Association of history of gestational diabetes with long- term cardiovascular disease risk in a large prospective cohort of US women. JAMA Intern Med 2017 Oct 16 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29049820
Gunderson EP, Jaffe MG. Pregnancy and subsequent glucose intolerance in women of childbearing age: Heeding the early warning signs for primary prevention of cardiovascular disease in women. JAMA Intern Med 2017 Oct 16; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/29049465 - ↑ 21.0 21.1 Senat MV, Affres H, Letourneau A et al Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes. A Randomized Clinical Trial. JAMA. 2018;319(17):1773-1780 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29715355 https://jamanetwork.com/journals/jama/fullarticle/2679942
Coustan DR, Barbour L Insulin vs Glyburide for Gestational Diabetes. JAMA. 2018;319(17):1769-1770. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29715338 https://jamanetwork.com/journals/jama/fullarticle/2679921 - ↑ 22.0 22.1 Magnus MC. Miliku K, Bauer A et al Vitamin D and risk of pregnancy related hypertensive disorders: mendelian randomisation study. BMJ 2018;361:k2167 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29925546 https://www.bmj.com/content/361/bmj.k2167
- ↑ 23.0 23.1 23.2 Powe CE, Bryant A Oral Alternatives to Insulin for Gestational Diabetes? NEJM Journal Watch. July 9, 2018 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
- ↑ 24.0 24.1 H Al Wattar B, Dodds J, Placzek A et al Mediterranean-style diet in pregnant women with metabolic risk factors (ESTEEM): A pragmatic multicentre randomised trial. PLOS Medicine. July 23, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31335871 Free Article https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002857
- ↑ 25.0 25.1 Dandjinou M, Sheehy O, Berard A Antidepressant use during pregnancy and the risk of gestational diabetes mellitus: a nested case-control study. BMJ Open. 2019 Oct 1;9(9):e025908. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31575566 Free full text https://bmjopen.bmj.com/content/9/9/e025908
- ↑ 26.0 26.1 Yu Y, Arah OA, Liew Z et al Maternal diabetes during pregnancy and early onset of cardiovascular disease in offspring: population based cohort study with 40 years of follow-up. BMJ 2019;367:l6398 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31801789 https://www.bmj.com/content/367/bmj.l6398
- ↑ 27.0 27.1 NEJM Knowledge+ Question of the Week for June 13, 2023 https://knowledgeplus.nejm.org/question-of-week/5168/
- ↑ 28.0 28.1 Boggess KA et al. Metformin plus insulin for preexisting diabetes or gestational diabetes in early pregnancy: The MOMPOD randomized clinical trial. JAMA 2023 Dec 12; 330:2182. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38085312 PMCID: PMC10716718 (available on 2024-06-12) https://jamanetwork.com/journals/jama/fullarticle/2812641
Dunne F et al. Early metformin in gestational diabetes: A randomized clinical trial. JAMA 2023 Oct 24; 330:1547. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37786390 PMCID: PMC10548359 (available on 2024-04-03) https://jamanetwork.com/journals/jama/fullarticle/2810387
Feig DS. Metformin for diabetes in pregnancy: Are we closer to defining its role? JAMA 2023 Dec 12; 330:2167. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38085322 https://jamanetwork.com/journals/jama/fullarticle/2812667 - ↑ 29.0 29.1 Cesta CE et al. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern Med 2023 Dec 11; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/38079178 PMCID: PMC10714281 Free PMC article https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2812743
- ↑ Agency for Healthcare Research and Quality (AHRQ) Screening and Diagnosing Gestational Diabetes Mellitus http://www.ahrq.gov/clinic/tp/gdmexuptp.htm